Background: Tenofovir-lamivudine-dolutegravir (TLD) is an effective, single-tablet ART regimen but the causes of virologic failure that can occur despite adherence to TLD are incompletely understood, especially when resistance mutations in integrase (IN) are absent. Noncanonical resistance mutations in nucleocapsid (NC) have been selected in cell culture and are associated with decreased dolutegra
Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-Dolutegravir
calendar_today
July 2, 2026
person
Penrose, K. J., Hikichi, Y., Sethi, R., Goetz, B. J., Siffert, L. O., Valiyaparmbil, S. A., Wallis, C. L., McCarthy, C., Wooley, E., Chandran, U. R., Kityo, C. M., Flexner, C., Hughes, M. D., Koenig, S. P., Freed, E. O., Mellors, J. W., Parikh, U. M., ACTG A5381/Hakim Study Team
domain
medrxiv